WFDC2 and ovarian cancer: HE4 was reported as a promising serum biomarker following its detection in ovarian cancer tissue, mainly serous [16,17], achieving higher sensitivity than CA125 alone, with a sensitivity of 72.9% and specificity of 95% [18,19,20].